BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 11486401)

  • 1. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
    Coleman M; Leonard J; Shuster MW; Kaufman TP
    Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
    Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
    Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
    Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
    Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
    van Besien K; Rodriguez A; Tomany S; Younes A; Donato M; Sarris A; Giralt S; Mehra R; Andersson B; Gajewski J; Champlin R; Cabanillas F
    Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
    Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
    Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
    J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease.
    Bonfante V; Viviani S; Devizzi L; Di Russo A; Di Nicola M; Magni M; Matteucci P; Grisanti S; Valagussa P; Bonadonna G; Gianni AM
    Eur J Haematol Suppl; 2001 Jul; 64():51-5. PubMed ID: 11486403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
    Fan Y; Huang ZY; Luo LH; Yu HF
    Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
    Bo LJ; Liang AB; Liu B; Chen YH; Wang F; Jin XP
    Ai Zheng; 2006 Dec; 25(12):1553-6. PubMed ID: 17166385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin].
    Okamoto M; Maruyama F; Tsuzuki M; Nomura T; Miyazaki H; Wakita M; Kojima H; Sobue R; Matsui T; Ino T
    Rinsho Ketsueki; 1994 Jul; 35(7):635-41. PubMed ID: 8065017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
    Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
    Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.